SEC Form 4 · accession 0001209191-18-028718
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Morneau
Officer — VP, Finance and Administration
Period of report
May 4, 2018
Accepted (ET)
May 8, 2018 · 8:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per share | May 4, 2018 | F | 7,616 | $4.22 | D | 94,035 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock.